PT  - JOURNAL ARTICLE
AU  - SHIMOZATO, NAOTAKA
AU  - NAMISAKI, TADASHI
AU  - OKANO, AKIHIRO
AU  - OHANA, MASAYA
AU  - KINOSHITA, DAISUKE
AU  - KAWASAKI, TOSHIHIKO
AU  - AIHARA, YOSUKE
AU  - NAKATANI, TOSHIYA
AU  - KINOSHITA, HIROKI
AU  - ANN, TATSUICHI
AU  - SAITO, KO
AU  - YOSHIDA, MOTOYUKI
AU  - YOSHIJI, HITOSHI
TI  - Efficacy and Safety of Lenvatinib for Patients With Advanced Hepatocellular Carcinoma: A Retrospective, Real-world Study Conducted in Japan
AID  - 10.21873/anticanres.15471
DP  - 2022 Jan 01
TA  - Anticancer Research
PG  - 173--183
VI  - 42
IP  - 1
4099  - http://ar.iiarjournals.org/content/42/1/173.short
4100  - http://ar.iiarjournals.org/content/42/1/173.full
SO  - Anticancer Res2022 Jan 01; 42
AB  - Aim: We evaluated real-world efficacy and toxicity of lenvatinib in 142 patients with advanced hepatocellular carcinoma (HCC) at six tertiary referral centres. Patients and Methods: The patients with advanced HCC treated with lenvatinib were grouped into two categories based on REFLECT criteria for analysis of efficacy and safety. The primary endpoint was progression-free survival (PFS). Results: The objective response rate (ORR) at week 12 of therapy was 41.5%, with a median PFS of 176 days. Child–Pugh score of 5 points, the presence of extrahepatic metastasis and adverse effects grade 2 or higher were considered independent factors associated with both better PFS and ORR. The ORR for patients who fulfilled the REFLECT inclusion criteria was significantly higher than that for those who did not. However, no significant differences in PFS were observed between the two groups. The incidence rate of adverse effects grade 3 or higher was 40.1%, which was similar for the two groups. Conclusion: Lenvatinib is safe and effective for patients, whether or not they satisfy REFLECT criteria. The result warrants replication in a larger study.